Michelle L Lifton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7314155/publications.pdf Version: 2024-02-01



MICHELLE LLIETON

#	Article	lF	CITATIONS
1	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	12.6	789
2	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017, 543, 248-251.	27.8	699
3	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 2022, 603, 493-496.	27.8	326
4	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature, 2021, 596, 268-272.	27.8	290
5	Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination. Journal of Virology, 2001, 75, 5151-5158.	3.4	186
6	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 2022, 185, 1549-1555.e11.	28.9	59
7	Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11088-11093.	7.1	58
8	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell, 2021, 184, 3467-3473.e11.	28.9	49
9	Simian immunodeficiency virus (SIV)–specific cytotoxic T lymphocytes in gastrointestinal tissues of chronically SIV-infected rhesus monkeys. Blood, 2001, 98, 3757-3761.	1.4	41
10	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
11	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
12	Human Immunodeficiency Virus Type 1 Envelope Epitope-Specific CD4+ T Lymphocytes in Simian/Human Immunodeficiency Virus-Infected and Vaccinated Rhesus Monkeys Detected Using a Peptide-Major Histocompatibility Complex Class II Tetramer. Journal of Virology, 2000, 74, 8751-8756.	3.4	30
13	An IL-2/Ig Fusion Protein Influences CD4+T Lymphocytes in Naive and Simian Immunodeficiency Virus-Infected Rhesus Monkeys. AIDS Research and Human Retroviruses, 2001, 17, 873-886.	1.1	20
14	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology, 2021, 22, 1294-1305.	14.5	20
15	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Open Forum Infectious Diseases, 2016, 3, ofw034.	0.9	15
16	Strong T _H 1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. Science Translational Medicine, 2019, 11, .	12.4	14
17	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLoS Biology, 2022, 20, e3001609.	5.6	14
18	Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. Vaccine Journal, 2014, 21, 1385-1395.	3.1	13

MICHELLE L LIFTON

#	Article	IF	CITATIONS
19	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques. Science Translational Medicine, 2022, 14, eabm4996.	12.4	13
20	Functional Perturbation of Mucosal Group 3 Innate Lymphoid and Natural Killer Cells in Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus-Infected Infant Rhesus Macaques. Journal of Virology, 2020, 94, .	3.4	6
21	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. Npj Vaccines, 2021, 6, 15.	6.0	5